A Study to Explore the Effect of Sepranolone in Tourette Syndrome
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
30 subjects aged 12 to 45 years of age diagnosed with Tourette Syndrome with a YGTSS score >
20 during 30 days of baseline observation to be randomized to
1. continued present stable treatment (10 subjects) or
2. continued present stable treatment plus 10 mg of Sepranolone injected s.c. twice weekly
for 12 weeks (20 patients) followed by one month of observation
Primary objective: to investigate the efficacy of Sepranolone to reduce tic severity in
patients with Tourette syndrome after 12 weeks